Champions Oncology to Announce Second Quarter Financial Results on Monday, December 15, 2025
Rhea-AI Summary
Champions Oncology (NASDAQ:CSBR) will report financial and operational results for the second quarter ended October 31, 2025 on Monday, December 15, 2025 after market close.
The company will host a conference call the same day at 4:30 P.M. EST (1:30 P.M. PST). Domestic dial-in: 888-506-0062; International: 973-528-0011; access code: 691139.
A replay will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) with passcode 53331, or via the company's investor website within 72 hours.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: notable gains in QNCX (8.97%) and SRZN (11.8%), while MGNX declined (-1.44%). This mix suggests CSBR’s modest 0.67% rise is more stock-specific than part of a broad sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Sep 15 | Quarterly results | Negative | +21.5% | Q1 FY2026 results with margin compression and shift to operating loss. |
| Sep 15 | Quarterly results | Negative | +21.5% | Q1 FY2026 revenue flat, higher expenses drove operating loss and lower EBITDA. |
| Sep 10 | Earnings date set | Neutral | +0.3% | Scheduled Q1 fiscal 2025 results and conference call details. |
| Jul 23 | Annual results | Positive | -14.2% | Record FY2025 revenue and profitability but softer Q4 performance metrics. |
| Jul 21 | Earnings date set | Neutral | +0.3% | Announcement of Q4 and year-end release date and investor call access. |
Earnings result releases have triggered sharp, sometimes contrarian moves, while simple earnings-date announcements have seen minimal price reaction.
Over the last six months, Champions Oncology has reported record annual revenue of $57 million with improved profitability, followed by Q1 FY2026 results showing $14.0 million revenue but margin pressure and an operating loss. Despite mixed fundamentals, those Q1 results coincided with a strong 21.52% price gain, contrasting with a -14.19% reaction to the annual report. Prior earnings-date announcements on July 21 and September 10 produced only marginal moves, similar in nature to today’s scheduling release.
Market Pulse Summary
This announcement schedules Champions Oncology’s Q2 FY2026 financial results for December 15, 2025, with a conference call at 4:30 P.M. EST. Recent history shows mixed fundamental signals: record annual revenue alongside margin pressure and an operating loss in Q1 FY2026. Investors may focus on upcoming updates to revenue growth, gross margin trends, and cash position, comparing them to prior milestones such as the $57 million fiscal 2025 revenue and earlier EBITDA performance.
AI-generated analysis. Not financial advice.
HACKENSACK, NJ / ACCESS Newswire / December 8, 2025 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the second quarter ended October 31, 2025, on Monday, December 15, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 691139. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 53331, or by accessing the investors section of the company's website within 72 hours.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Gavin Cooper - Vice President, Global Marketing
gcooper@championsoncology.com
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Champions Oncology (CSBR) release Q2 2026 results and when is the conference call?
How can investors join the Champions Oncology (CSBR) earnings call on December 15, 2025?
Will there be a replay of the Champions Oncology (CSBR) December 15, 2025 call and how long will it be available?
What time is the Champions Oncology (CSBR) call in Pacific Time on Dec 15, 2025?
Where can I find the Champions Oncology (CSBR) earnings call materials after the Dec 15, 2025 release?
